Treatment of anxiety disorders with venlafaxine XR

Expert Review of Neurotherapeutics

Volumn 6, Issue 3, 2006, Pages 269-282

  Thase, Michael E ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Anxiety; Generalized anxiety disorder; Obsessive compulsive disorder; Panic disorder; Posttraumatic stress disorder; Serotonin norepinephrine reuptake inhibitor; Social anxiety disorder; Venlafaxine

Indexed keywords

ALCOHOL; ALPRAZOLAM; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; LITHIUM SALT; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PAROXETINE; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VASOPRESSIN; VENLAFAXINE;

ALCOHOLISM; ANOREXIA; ANXIETY DISORDER; ASTHENIA; BLEEDING; BLOOD BRAIN BARRIER; BLOOD PRESSURE VARIABILITY; BODY WEIGHT DISORDER; CAPILLARY RESISTANCE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DIZZINESS; DOSE CALCULATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG OVERDOSE; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSPHORIA; ECG ABNORMALITY; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOMANIA; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INSOMNIA; MAJOR DEPRESSION; MANIA; MENTAL INSTABILITY; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PANIC; PARESTHESIA; PLASMA PROTEIN BINDING; POSTMARKETING SURVEILLANCE; POSTTRAUMATIC STRESS DISORDER; PSYCHOLOGICAL RATING SCALE; REMISSION; REVIEW; SEIZURE SUSCEPTIBILITY; SEXUAL DYSFUNCTION; SOCIAL PHOBIA; SOMNOLENCE; STEADY STATE; SUBSTANCE ABUSE; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; SUSTAINED DRUG RELEASE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; THROMBOCYTE AGGREGATION; TREATMENT INDICATION; WEIGHT CHANGE; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANXIETY DISORDERS; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; TREATMENT OUTCOME;

EID: 33645875900     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.3.269     Document Type: Review

References (93)

1. Robins L, Helzer J, Weissman M et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch. Gen. Psychiatry 41, 949-958 (1984).
2. Kessler R, McGonagle K, Zhao S et al. Lifetime and 12-month prevalence of DSM-III-r psychiatric disorders in the united states. Results from the national comorbidity survey. Arch. Gen. Psychiatry 51, 8-19 (1994).
3. Kessler RC, Berglund P, Demler O, Jin R, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 93-602 (2005).
4. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 617-627 (2005).
5. Melartin T, Rytsala H, Leskela U, Lestela-Mielonen P, Sokero T, Isometsa E. Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa depression study. J. Clin. Psychiatry 63, 126-134 (2002).
6. Greenberg P, Sisitsky T, Kessler R et al. The economic burden of anxiety disorders in the 1990s. J. Clin. Psychiatry 60, 427-435 (1999).
7. DuPont R, DuPont C, Rice D. Economic costs of anxiety disorders. In: Textbook of Anxiety Disorders. Stein D, Hollander E (Eds), American Psychiatric Publishing, DC, USA 475-483, (2002).
8. Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Undertreatment of Anxiety Disorders. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 629-640 (2005).
9. Ballenger J, Davidson J, Lecrubler Y et al. Consensus statement on generalized anxiety disorder from the international consensus group on depression and anxiety. J. Clin. Psychiatry 62(Suppl. 11), 53-58 (2001).
10. Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J. Clin. Psychiatry 63(Suppl. 14), 9-16 (2002).
11. American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. Am. J. Psychiatry 155(Suppl. 5), 1-34 (1998).
12. The Expert Consensus Panel for obsessive-compulsive disorder. Treatment of obsessive-compulsive disorder. J. Clin. Psychiatry 58(Suppl. 4), 2-72 (1997).
13. Ursano RJ, Bell C, Eth S et al. Practice guideline for the treatment of patients with acute stress disorder and post-traumatic stress disorder. Am. J. Psychiatry 161(Suppl. 11), 3-31 (2004).
14. Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J. Clin. Psychopharmacol. 23, 250-259 (2003).
15. Pecknold JC. A risk-benefit assessment of buspirone in the treatment of anxiety disorders. Drug Saf. 16, 118-132 (1997).
16. Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 9, 97-140 (2003).
17. Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB. Antidepressant biochemical profile of the novel bicyclic compound wy-45,030, an ethyl cyclohexanol derivative. Biochem. Pharmacol. 35, 4493-4497 (1986).
18. Thase ME, Sloan DME. Venlafaxine. In: Textbook of Psychopharmacology Third Edition, Schatzberg AF, Nemeroff CB (Eds.), American Psychiatric Publishing Inc., DC, USA, 349-360 (2003).
19. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol. Psychiatry 55, 320-322 (2004).
20. Stahl SM. Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. J. Clin. Psychiatry 59(Suppl. 4), 5-14 (1998).
21. Beique J, de Montigny C, Blier P, Debonnel G. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat. Neuropharmacology 24, 1800-1812 (2000).
22. Roseboom PH, Kalin NH. Neuropharmacology of venlafaxine. Depress. Anxiety 12(Suppl. 1), 20-29 (2000).
23. Baron BM, Ogden AM, Siegel BW, Stegeman J, Ursillo RC, Dudley MW. Rapid down regulation of β-adrenoceptors by co-administration of desipramine and fluoxetine. Eur. J. Pharmacol. 154, 125-134 (1988).
24. Bitsios P, Szabadi E, Bradshaw CM. Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man. J. Clin. Psychiatry 59, 502-508 (1998).
25. Abdelmawla AH, Langley RW, Szabadi E, Bradshaw CM. Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein. Br. J. Clin. Pharmacol. 48, 345-354 (1999).
26. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch. Gen. Psychiatry 57, 503-509 (2000).
27. Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress. Anxiety. 12(Suppl. 1), 30-44 (2000).
28. Ball S, Ahern D, Scatina J, Kao J. Venlafaxine: In vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br. J. Clin. Pharmacol. 43, 619-626 (1997).
29. Gitlin M. Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome. J. Clin. Psychopharmacol. 17, 66-67 (1997).
30. Davidson J, Meoni P, Haudiquet V, Cantillon M, Hackett D. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress. Anxiety 16(1), 4-13 (2002).
31. Silverstone P, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 study group. J. Clin. Psychiatry 60, 22-28 (1999).
32. Gorman JM, Papp LA. Efficacy of venlafaxine in mixed depression-anxiety states. Depress. Anxiety. 12(Suppl. 1), 30-44 (2000).
33. Rudolph RL, Entsuah R, Chitra R. A metaanalysis of the effects of venlafaxine on anxiety associated with depression. J. Affect. Disord. 47, 55-62 (1998).
34. De Nayer A, Geerts S, Ruelens L et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int. J. Neuropsychopharmacol. 5, 115-120 (2002).
35. Silverstone P, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J. Clin. Psychiatry 62, 523-529 (2001).
36. Davidson J, Du Pont R, Hedges D, Haskins J. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J. Clin. Psychiatry 60, 528-535 (1999).
37. Hackett D, Haudiquet V, Salinas E. A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder. Eur. Psychiatry 18, 182-187 (2003).
38. Rickels K, Pollack M, Sheehan D, Haskins J. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am. J. Psychiatry 157, 968-974 (2000).
39. Gelenberg A, Lydiard R, Rudolph R, Aguiar L, Haskins J, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 283, 3082-3088 (2000).
40. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (er) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br. J. Psychiatry 179, 15-22 (2001).
41. Montgomery S, Sheehan D, Meoni P, Haudiquet V, Hackett D. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J. Psychiatr. Res. 36, 209-217 (2002).
42. Montgomery SA, Mahe V, Haudiquet V, Hackett D. Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: results of a survival analysis. J. Clin. Psychopharmacol. 22, 561-567 (2002).
43. Katz IR, Reynolds CF 3rd, Alexopoulos GS, Hackett D. Venlafaxine XR as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J. Am. Geriatr. Soc. 50, 18-25 (2002).
44. Lenox-Smith AJ, Reynolds A. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. Br. J. Gen. Pract. 53, 772-777 (2003).
45. Nimatoudis I, Zissis NP, Kogeorgos J, Theodoropoulou S, Vidalis A, Kaprinis G. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. Int. Clin. Psychopharmacol. 19, 331-336 (2004).
46. Muller JE, Koen L, Seedat S, Stein DJ. Social anxiety disorder: current treatment recommendations. CNS Drugs 19, 377-391 (2005).
47. Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine XR in adult outpatients with generalized social anxiety disorder. J. Clin. Psychopharmacol. 24, 488-496 (2004).
48. Liebowitz MR, Mangano RM, Bradwejn J, Asnis G. SAD Study Group. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J. Clin. Psychiatry 66, 238-247 (2005).
49. Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Br. J. Psychiatry 185, 37-45 (2004).
50. Allgulander C, Mangano R, Zhang J et al. Efficacy of venlafaxine XR in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum. Psychopharmacol. 19, 387-396 (2004).
51. Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch. Gen. Psychiatry 62, 190-198 (2005).
52. Mallick R, Mangano R, Shrivastava R. Improvement in functionality with treatment of generalized social anxiety disorder: Venlafaxine XR vs placebo. Eur. Neuropsychopharmacol. 12(Suppl. 3), S356 (2002).
53. Rynn M, March J, Tourian K, Mangano R. Safety and efficacy of venlafaxine XR in the treatment of pediatric social anxiety disorder. Eur. Neuropsychopharmacol. 14(Suppl. 3), S306 (2004).
54. Pollack MH, Worthington JJ 3rd, Otto MW et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol. Bull. 32, 667-670 (1996).
55. Bradwejn J, Emilien G, Whitaker T. Treatment of panic disorder with venlafaxine XR. Br. J. Psychiatry 187, 352-359 (2005).
56. Liebowitz M, Asnis G, Tzanis E, Whitaker T. A double blind placebo controlled trial of venlafaxine XR in the short-term treatment of panic disorder. Eur. Neuropsychopharmacol. 14(Suppl. 3), S305-S306 (2004).
57. Pollack M, Lepola U, Emilien G, Tzanis E, Whitaker T. Venlafaxine XR and paroxetine in the short-term treatment of panic disorder. Eur. Neuropsychopharmacol. 13(Suppl. 4), S378 (2003).
58. Pollack M, Whitaker T, Mangano R, Tazanis E. A comparison of venlafaxine XR and paroxetine in the treatment of outpatients with panic disorder. Poster presented at the Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 12-16, (2004).
59. Ferguson J, Whitaker T, Mangano R, Tzanis E. Preventing relapse of panic disorder in adult outpatient responders to venlafaxine XR. Poster presented at the Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 12-16, (2004).
60. Davidson J, Lipschitz A, Musgnung J. Venlafaxine XR and sertraline in PTSD: a placebo-controlled study. Eur. Neuropsychopharmacol. 13(Suppl. 4), S380 (2003).
61. Davidson J, Baldwin D, Stein DJ et al. Treatment of postratumatic stress disorder with venlafaxine XR: A 6-month randomized controlled trial. Poster presented at the Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 12-16, (2004).
62. Schwartz AC, Rothbaum BO. Review of sertraline in post-traumatic stress disorder. Expert Opin. Pharmacother. 3, 1489-1499 (2002).
63. Albert U, Aguglia E, Maina G, Bogetto F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J. Clin. Psychiatry 63, 1004-1009 (2002).
64. Denys D, van der Wee N, van Megen HJ, Westenberg HG. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J. Clin. Psychopharmacol. 23, 568-575 (2003).
65. Denys D, van Megen HJ, van der Wee N, Westenberg HG. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J. Clin. Psychiatry 65, 37-43 (2004).
66. Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 325(7376), 1332-1333 (2002).
67. Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 96, 369-374 (2003).
68. Mines D, Hill D, Yu H, Novelli L Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiol. Drug Saf. 14, 367-372 (2005).
69. Mackay FR, Dunn NR, Martin RM, Pearce GL, Freemantle SN, Mann RD. Newer antidepressants: a comparison of tolerability in general practice. Br. J. Gen. Pract. 49(448), 892-896 (1999).
70. Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can. J. Psychiatry 47, 174-180 (2002).
71. Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J. Clin. Psychiatry 61, 276-281 (2000).
72. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J. Clin. Psychiatry 62(Suppl. 3), 10-21 (2001).
73. Clayton AH, Pradko JF, Croft HA et al. Prevalence of sexual dysfunction among newer antidepressants. J. Clin. Psychiatry 63, 357-366 (2002).
74. Baldwin DS, Montgomery SA, Nil R, Lader M. Discontinuation symptoms in depression and anxiety disorders. Int. J. Neuropsychopharmacol. 19, 1-12 (2005).
75. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J. Clin. Psychiatry 53, 502-508 (1998).
76. Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. J. Clin. Psychiatry 56, 574-579 (1995).
77. Montgomery SA, Entsuah R, Hackett D, Kunz NR, Rudolph RL. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J. Clin. Psychiatry 65, 328-336 (2004).
78. Simon JS, Aguier LM, Kunz NR, Lei D. Extended release venlafaxine in relapse prevention for patients with major depressive disorder. J. Psychiatric Research 38, 249-257 (2004).
79. Schlienger RG, Fischer LM, Jick H, Meier CR. Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. Drug Saf. 27, 1157-1165 (2004).
80. Post RM, Altshuler LL, Frye MA et al. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord. 3, 259-265 (2001).
81. Vieta E, Martinez-Aran A, Goikolea JM et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J. Clin. Psychiatry 63, 508-512 (2002).
82. Simon NM, Otto MW, Wisniewski SR et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am. J. Psychiatry 161, 2222-2229 (2004).
83. Murray ML, Thompson M, Santosh PJ, Wong IC. Effects of the Committee on Safety of Medicines Advice on Antidepressant Prescribing to Children and Adolescents in the UK. Drug Saf. 28, 1151-1157 (2005).
84. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363, 1341-1345 (2004).
85. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 178, 234-241 (2001).
86. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br. J. Psychiatry. 180, 396-404 (2002).
87. Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, Malvini L, Barbui C, Cipriani AM. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst. Rev. 4, CD004185 (2005).
88. Thase ME. Comparing the efficacy of the newer antidepressants. In: Nuevas Perspectives en la Depresión, Gilaberte I (Ed.), Aula Médica Endiciones, Madrid, Spain 253-286 (2004).
89. Heuzenroeder L, Donnelly M, Haby MM et al. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Aust. NZ J. Psychiatry 38, 602-612 (2004).
90. Guest JF, Russ J, Lenox-Smith A. Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom. Eur. J. Health Econ. 6(2), 136-145(2006).
91. Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 23, 155-167 (2005).
92. Wade AG, Toumi I, Hemels ME. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr. Med. Res. Opin. 2, 631-642 (2005).
93. Thase ME. Comparing the methods used to compare antidepressants. Psychopharmacol. Bull. 36(Suppl .1), 4-17 (2002).